Figure 3.

Population pharmacokinetic model–predicted covariate effects on steady‐state (A) olanzapine C_max,ss, (B) olanzapine AUC_tau, (C) samidorphan C_max,ss, and (D) samidorphan AUC_tau.

^aReference C_max,ss for olanzapine is 31.7 ng/mL.

^bReference AUC_tau for olanzapine is 635 ng · h/mL.

^cReference C_max,ss for samidorphan is 33.4 ng/mL.

^dReference AUC_tau for samidorphan is 284 ng · h/mL.

The solid vertical line represents no impact of the covariate using a healthy individual with the following characteristics as a reference subject: age, 36 years; weight, 70 kg; non‐Black, nonsmoking man, with normal hepatic and renal function receiving once‐daily oral OLZ/SAM 10 mg/10 mg in a fasted condition. Dashed vertical lines are at 0.8‐ and 1.25‐fold of this value.

AUC_tau, area under the plasma concentration‐time curve over the daily dosing interval at steady state; C_max,ss, maximum concentration at steady state; PI, prediction interval.